Real-life Evaluation of WEGOVY (Semaglutide) Treatment in Adults With Monogenic Obesity (ObGeSema)

NCT06380426

Status	RECRUITING
Sponsor	Assistance Publique - Hôpitaux de Paris
Enrollment	175 participants

Key Eligibility Criteria

Inclusion (4)

- Adult Patients (e18 years)having already initiated a treatment with SEMAGLUTIDE (WEGOVY®) or with a physician's decision to initiate treatment in the standard care in the near future. All patients having initiated a treatment will be proposed to participate, including those having already stopped the treatment at the time of study initiation.
- Confirmation of monogenic obesity, as practiced in clinical routine, by the presence of a pathogenic or likely pathogenic variant in a gene with leptin-melanocortin pathway described in PNDS (https://www.has-sante.fr/jcms/p_3280217/fr/generique-obesites-de-causes-rares)
- Patients duly informed and not objecting to participate in the study
- Patients affiliated to a social security scheme or State Medical Assistance (AME).

Exclusion (1)

- Pregnant and breastfeeding women

Locations (2 total)

Centre de référence Syndrome de Prader-Willi et autres obésités avec troubles du comportement alimentaire (PRADORT). Service de Nutrition, GH Pitié-Salpêtrière, APHP, Paris, France
CHU Pitié Salpêtrière - APHP, Paris, France